Who is sponsoring NCT00803283?

NCT00803283 is sponsored by Johnson & Johnson Taiwan Ltd.

What condition does NCT00803283 study?

NCT00803283 studies Cancer Pain.

What drugs are being tested in NCT00803283?

Interventions: Hydromprphone Hydrochloride (HCl) OROS, Morphine Sustain Release (SR).

What is the status of NCT00803283?

NCT00803283 is currently TERMINATED.

Last reviewed 2013-08-08 · How we verify

A Randomized, Open-Labeled, Multi-Center Study to Investigate the Safety and Efficacy of OROS Hydromorphone HCl Comparing With Morphine SR in Cancer Pain Patients

NCT00803283 Phase 3 TERMINATED Results posted

The purpose of this study is to evaluate the effectiveness and safety of Osmotic Release Oral System (OROS) hydromorohone Hydrochloride (HCl) compared with morphine sustain release (SR) in participants with chronic (lasting a long time) malignant (cancerous) cancer pain.

Details

Lead sponsor	Johnson & Johnson Taiwan Ltd
Phase	Phase 3
Status	TERMINATED
Enrolment	2
Start date	2008-11
Completion	2008-12

Conditions

Cancer Pain

Interventions

Hydromprphone Hydrochloride (HCl) OROS
Morphine Sustain Release (SR)

Primary outcomes

Brief Pain Inventory (BPI) Questionnaire Item 3 "Worst Pain" Score at Day 14 — Day 14
The BPI is a questionnaire designed to assess the severity and impact of pain on quality of life. Total score ranges from 0=no pain to 10=extreme pain. BPI Questionnaire Item 3 "Worst Pain" will be assessed using the BPI questionnaire, score ranges from 0 (no pain) to 10 (pain as bad as you can imagine).
BPI Questionnaire Item 3 "Worst Pain" Score at Day 28 — Day 28
The BPI is a questionnaire designed to assess the severity and impact of pain on quality of life. Total score ranges from 0=no pain to 10=extreme pain. BPI questionnaire Item 3 "Worst Pain" will be assessed using the BPI questionnaire, score ranges from 0 (no pain) to 10 (pain as bad as you can imagine).